Robert Adelman

Dr. Adelman has a 30+ year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across multiple venture capital funds.

Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led Fund I's investments into Aragon Pharmaceuticals (acquired by Johnson and Johnson) and Seragon Pharmaceutical (acquired by Genentech/Roche). Dr. Adelman is a member of the Board of Solstice Biologics, Heart Metabolics, Metacrine, Alexo Therapeutics, Precision Biosciences, Adheren, and Apellis.